However, even without drug targeting, induction of MITF, to levels seen in melanocytes or above what is tolerated by even the highly pigmented tumour cell types, would seem to be incompatible with melanoma progression as it can inhibit cell cycle progression (Goding, 2013). The gene discussed is MITF; the disease is melanoma.